Novartis's Kymriah Fails to Meet Primary Endpoint in Phase 3 Study
24 Agosto 2021 - 2:47AM
Dow Jones News
By Olivia Bugault
Novartis AG said Tuesday that its Phase 3 Belinda study
assessing the efficacy and safety of Kymriah cell therapy as a
second-line treatment for lymphoma compared with another standard
treatment failed to meet its primary endpoint.
The primary endpoint "of event-free survival for patients with
aggressive B-cell non-Hodgkin lymphoma who had primary refractory
disease or who relapsed within 12 months of first-line treatment"
wasn't met, the Swiss pharma said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
August 24, 2021 01:46 ET (05:46 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
